Literature DB >> 11836415

Role of an intact splenic microarchitecture in early lymphocytic choriomeningitis virus production.

Stefan Müller1, Lukas Hunziker, Susanne Enzler, Myriam Bühler-Jungo, James P Di Santo, Rolf M Zinkernagel, Christoph Mueller.   

Abstract

An acute infection with lymphocytic choriomeningitis virus (LCMV) is efficiently controlled by the cytotoxic-T-cell (CTL) response of the host, and LCMV titers in the spleen and peripheral solid organs usually fall sharply after day 4 to 6 postinfection. Surprisingly, infection of immunodeficient recombination-activating gene 2-deficient (RAG2-/-) mice with 5 x 10(2) PFU of LCMV-WE causes about 80-fold-lower LCMV titers in the spleen on day 4 postinfection compared with C57BL/6 control mice. This could not be attributed to NK cell activity, since common gamma-chain-deficient RAG2-/- mice lacking NK cells show low LCMV titers comparable to those for RAG2-/- mice. Furthermore, the reduced early LCMV production in spleens could not be explained by an enhanced gamma interferon production in RAG2-/- mice. Analysis of mutant mice exhibiting various defects in the splenic microarchitecture, including (i) tumor necrosis factor alpha-negative (TNF-alpha-/-), lymphotoxin alpha-negative (LTalpha-/-), B-cell-deficient muMT mice, (ii) immunoglobulin M-negative mice, and (iii) RAG2-/- mice reconstituted with wild-type versus TNF-alpha-/- LTalpha-/- B cells, revealed a clear correlation between an intact splenic marginal zone, rapid early replication of LCMV in the spleen, and efficient CTL induction. These results suggest that by the preferential infection of the highly organized splenic microarchitecture, LCMV seems to successfully exploit one of the key elements in the chain of the adaptive immune system. Not only does the early tropism of LCMV for the splenic marginal zone trigger a potent immune response, but at the same time the marginal zone may also become a target of early CTL-mediated immunopathology that impairs immune responsiveness.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836415      PMCID: PMC153806          DOI: 10.1128/jvi.76.5.2375-2383.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

Review 1.  Cells in the marginal zone of the spleen.

Authors:  G Kraal
Journal:  Int Rev Cytol       Date:  1992

2.  Specific cytotoxic T cells eliminate B cells producing virus-neutralizing antibodies [corrected].

Authors:  O Planz; P Seiler; H Hengartner; R M Zinkernagel
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

Review 3.  Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity.

Authors:  R M Zinkernagel; S Ehl; P Aichele; S Oehen; T Kündig; H Hengartner
Journal:  Immunol Rev       Date:  1997-04       Impact factor: 12.988

4.  Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor.

Authors:  M Pasparakis; L Alexopoulou; M Grell; K Pfizenmaier; H Bluethmann; G Kollias
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

5.  Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice.

Authors:  D Kägi; B Ledermann; K Bürki; P Seiler; B Odermatt; K J Olsen; E R Podack; R M Zinkernagel; H Hengartner
Journal:  Nature       Date:  1994-05-05       Impact factor: 49.962

6.  Multiple immune abnormalities in tumor necrosis factor and lymphotoxin-alpha double-deficient mice.

Authors:  H P Eugster; M Muller; U Karrer; B D Car; B Schnyder; V M Eng; G Woerly; M Le Hir; F di Padova; M Aguet; R Zinkernagel; H Bluethmann; B Ryffel
Journal:  Int Immunol       Date:  1996-01       Impact factor: 4.823

7.  Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin.

Authors:  P De Togni; J Goellner; N H Ruddle; P R Streeter; A Fick; S Mariathasan; S C Smith; R Carlson; L P Shornick; J Strauss-Schoenberger
Journal:  Science       Date:  1994-04-29       Impact factor: 47.728

8.  Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression.

Authors:  P Borrow; C F Evans; M B Oldstone
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

9.  Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain.

Authors:  J P DiSanto; W Müller; D Guy-Grand; A Fischer; K Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

10.  Protective T cell-independent antiviral antibody responses are dependent on complement.

Authors:  A F Ochsenbein; D D Pinschewer; B Odermatt; M C Carroll; H Hengartner; R M Zinkernagel
Journal:  J Exp Med       Date:  1999-10-18       Impact factor: 14.307

View more
  21 in total

Review 1.  Role of lymphotoxin in experimental models of infectious diseases: potential benefits and risks of a therapeutic inhibition of the lymphotoxin-beta receptor pathway.

Authors:  Thomas W Spahn; Hans-Pietro Eugster; Adriano Fontana; Wolfram Domschke; Torsten Kucharzik
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

2.  Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection.

Authors:  Cherie T Ng; Brian M Sullivan; John R Teijaro; Andrew M Lee; Megan Welch; Stephanie Rice; Kathleen C F Sheehan; Robert D Schreiber; Michael B A Oldstone
Journal:  Cell Host Microbe       Date:  2015-05-13       Impact factor: 21.023

3.  Residues K465 and G467 within the Cytoplasmic Domain of GP2 Play a Critical Role in the Persistence of Lymphocytic Choriomeningitis Virus in Mice.

Authors:  Masaharu Iwasaki; Cherie T Ng; Beatrice Cubitt; Juan C de la Torre
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

4.  Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection.

Authors:  Yaming Wang; Melissa Swiecki; Marina Cella; Gottfried Alber; Robert D Schreiber; Susan Gilfillan; Marco Colonna
Journal:  Cell Host Microbe       Date:  2012-06-14       Impact factor: 21.023

5.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

6.  Persistent LCMV infection is controlled by blockade of type I interferon signaling.

Authors:  John R Teijaro; Cherie Ng; Andrew M Lee; Brian M Sullivan; Kathleen C F Sheehan; Megan Welch; Robert D Schreiber; Juan Carlos de la Torre; Michael B A Oldstone
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

Review 7.  Lymphotoxin in physiology of lymphoid tissues - Implication for antiviral defense.

Authors:  Ekaterina P Koroleva; Yang-Xin Fu; Alexei V Tumanov
Journal:  Cytokine       Date:  2016-09-09       Impact factor: 3.861

8.  Protracted course of lymphocytic choriomeningitis virus WE infection in early life: induction but limited expansion of CD8+ effector T cells and absence of memory CD8+ T cells.

Authors:  Elodie Belnoue; Paola Fontannaz-Bozzotti; Stéphane Grillet; Paul-Henri Lambert; Claire-Anne Siegrist
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

Review 9.  Mechanisms of lymphatic system-specific viral replication and its potential role in autoimmune disease.

Authors:  S-K Friedrich; P A Lang; J Friebus-Kardash; V Duhan; J Bezgovsek; K S Lang
Journal:  Clin Exp Immunol       Date:  2019-01       Impact factor: 4.330

10.  Sensitizing antigen-specific CD8+ T cells for accelerated suicide causes immune incompetence.

Authors:  Christoph Wasem; Diana Arnold; Leslie Saurer; Nadia Corazza; Sabine Jakob; Simon Herren; Claudio Vallan; Christoph Mueller; Thomas Brunner
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.